BioSpace News Archive

MRIdian to Bring Benefits of MRI-Guided Radiation Therapy to Veterans Throughout Ohio and the Surrounding Region

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced a partnership with Breakthrough Health, a Berlin-based technology company.

Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, announced it will host an educational webinar on Thursday, October 22, at 1:00 p.m. ET to review multiple aspects of Angelman syndrome, including its biological mechanism, and the Company’s OV101 development program.

Late-breaking abstracts explore cardiovascularoutcomes of patients with anemia in chronic kidney disease(CKD) treated with roxadustat, including associations with achieved hemoglobin levels and risk of Major Adverse Cardiovascular Events (MACE) and MACE+

OpSens Inc., a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary disease, announced it has been awarded a 3-year contract by a major American Group Purchasing Organization.

New CleanPlex® ACE2 & TMPRSS2 Panel Assesses Differences in Patients’ Genetic Susceptibility to COVID-19 Infection and to Developing Severe Disease

CytoSorbents Corporation and Aferetica srl, two pioneers in intensive care immunotherapy and blood purification, announce the European Union approval of Aferetica’s PerLife™ ex vivo organ perfusion system and CytoSorbents’ ECOS-300CY™ sorbent cartridge for the removal of inflammatory mediators during ex vivo organ perfusion.

Veeva Systems announced that Exact Sciences, a leading provider of cancer screening and diagnostic tests, selected Veeva Vault Clinical Suite to design and run its clinical studies.

NeuroRx, Inc., a clinical-stage pharmaceutical company developing small molecules for unmet medical needs, announced that Chairman and CEO Jonathan C.

In an unrelated development, apartnerinitiated Phase 2 development of an undisclosed asset, which triggers $0.5 million milestone payment to XOMA